Biomedical Engineering Reference
In-Depth Information
applicable to both types of heterogeneity. While is it expected that some aptam-
ers may be common to all types of lethal cancers, it cannot be taken as a given.
Every tumor may be different. However, these strategies give us the opportunity
to explore customized therapy for individual patients. Ultimately, one would like
to create a specific aptamer library for a particular patient. This could be particu-
larly useful in the surgical patient. Cancer tissue would be used to generate a
patient-specific library. This patient-specific library would then be used sys-
temically to scavenge and destroy micrometastases. If and when the tumor pro-
gresses, samples from the metastatic lesions could be used to generate new
libraries. In summary, therapeutic evolution should be able to outpace biologic
evolution.
6.
REFERENCES
1. Radman M, Matic I, Taddei F. 1999. Evolution of evolvability.
Ann NY Acad Sci
870
:146-155.
2. Greaves M. 2002. Cancer causation: the Darwinian downside of past success?
Lancet Oncol
3
:244-251.
3. Nowell PC. 1976. The clonal evolution of tumor cell populations.
Science
194
:23-28.
4. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer.
Cell
100
:57-70.
5. Nesse RM, Williams GC. 1998. Evolution and the origins of disease.
Sci Am
279
:58-65.
6. Schwab ED, Pienta KJ. 1996. Cancer as a complex adaptive system.
Med Hypotheses
47
:235-
241.
7. Coffey DS. 2001. Similarities of prostate and breast cancer: evolution, diet, and estrogens.
Urology
57
:31-38.
8. Pathak SK, Sharma, RA, Mellon JK. 2003. Chemoprevention of prostate cancer by diet-
derived antioxidant agents and hormonal manipulation [review].
Int J Oncol
22
:5-13.
9. Farinati F, Cardin R, Della Libera G, Herszenyi L, Marafin C, Molari A, Plebani M, Rugge M,
Naccarato R. 1994. The role of anti-oxidants in the chemoprevention of gastric cancer.
Eur J
Cancer Prev
3
(suppl 2):93-97.
10. Taddei F, Radman M, Maynard-Smith J, Toupance B, Gouyon PH, Godelle B. 1997. Role of
mutators in adaptive evolution.
Nature
387
:700-702.
11. Marusic M. 1991. Evolutionary and biological foundations of malignant tumors.
Med Hypothe-
ses
34
:282-287.
12. Pienta KJ, Partin AW, Coffey DS. 1989. Cancer as a disease of DNA organization and dy-
namic cell structure.
Cancer Res
49
:2525-2532.
13. Neumann AA, Reddel RR. 2002. Telomere maintenance and cancer—look, no telomerase.
Natl Rev Cancer
2
:879-884.
14.
Rubin H. 20:6. 2002. The disparity between human cell senescence
in vitro
and lifelong repli-
cation
in vivo
.
Nature Biotechnol
20
:75-81.
15.
Pienta KJ, Ward WS. 1994. An unstable nuclear matrix may contribute to genetic instability.
Med Hypotheses
42
:45-52.
16.
Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih Ie M, Vogelstein B, Lengauer C.
2002. The role of chromosomal instability in tumor initiation.
Proc Natl Acad Sci USA
99
:16226-16231.
17.
Anderson GR, Stoler DL, Brenner BM. 2001. Cancer: the evolved consequence of a destabi-
lized genome.
Bioessays
23
:1037-1046.
18.
Hoglund M, Gisselsson D, Sall T, Mitelman F. 2002. Coping with complexity: multivariate
analysis of tumor karyotypes.
Cancer Genet Cytogenet
135
:103-109.
